B7-H4 Monoclonal Antibody (188), PE, eBioscience™, Invitrogen™

Beschreibung

Description: The 188 monoclonal antibody was generated against and reacts with mouse B7-H4 also known as B7S1, B7X. Cross reactivity of this antibody to other proteins has not been determined. B7-H4 is a newly discovered member of the B7 family reported to inhibit T cell activation, cell cycle progression and IL-2 production. The ligand for B7-H4 has not been identified yet. Simultaneous double staining of cells with two anti-mouse B7-H4 antibodies, Clone 9 and 188, suggests that epitopes recognized by these mAbs are different and/or there is no steric hindrance when antibodies are used together. 188 stains mouse B7-H4 transfected cells and not spleen cells. Exact expression pattern of B7-H4 has not been fully characterized. Applications Reported: The 188 antibody has been reported for use in flow cytometric analysis. Applications Tested: The 188 antibody has been tested by flow cytometric analysis of transfected cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 μm post-manufacturing filtered.

B7-H4 (B7x, VTCN1) a costimulatory protein which is reported to function as a negative regulator of T-cell mediated immunity. Although B7-H4 binds an unknown receptor, it is thought to deliver an inhibitory signal to T-cells preventing their proliferation, cell cycle progression and interleukin-2 production. B7-H4 deficient mice are only minimally affected; suggesting B7-H4 is important in the fine tuning of the T-cell mediated immune response. B7-H4 is expressed on activated T-cells, B-cells, monocytes and dendritic cells. Aberrant expression has been associated with cancers of the lung, breast and ovary in humans. B7-H4 is expressed primarily on the membrane of lymphoid cells, and as an immunoinhibitory protein that interacts with receptors on the surface of T lymphocytes, it is involved in mediating cellular and humoral immune responses. Overexpression of B7-H4 is associated with certain malignancies, including ovarian and breast cancer, which may be a mechanism by which tumor cells suppress T cell immunity and facilitate tumor progression. Further, VTCN1 may be a useful biomarker for the early detection of ovarian cancer and Renal Cell Carcinoma (RCC).